Combination cancer immunotherapy and new immunomodulatory targets (Q34487698)

2 August 2017

1 reference

title

Combination cancer immunotherapy and new immunomodulatory targets (English)

1 reference

2 August 2017

1 reference

3

Gordon J Freeman

1 reference

2 August 2017

Kathleen M Mahoney

1

1 reference

2 August 2017

Paul D Rennert

series ordinal

2

1 reference

2 August 2017

language of work or name

1 reference

1 July 2015

1 reference

Nature Reviews Drug Discovery

2 August 2017

published in

1 reference

2 August 2017

volume

14

1 reference

2 August 2017

issue

8

1 reference

2 August 2017

page(s)

561-584

1 reference

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

2 August 2017

cites work

1 reference

HLA-binding properties of tumor neoepitopes in humans

31 March 2020

1 reference

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

31 March 2020

1 reference

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

31 March 2020

1 reference

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection.

31 March 2020

1 reference

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

31 March 2020

1 reference

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

31 March 2020

1 reference

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

31 March 2020

1 reference

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

31 March 2020

1 reference

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

31 March 2020

1 reference

Pembrolizumab for the treatment of non-small-cell lung cancer

31 March 2020

1 reference

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

31 March 2020

1 reference

Pembrolizumab versus Ipilimumab in Advanced Melanoma

31 March 2020

1 reference

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

31 March 2020

1 reference

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

31 March 2020

1 reference

Nivolumab plus ipilimumab in advanced melanoma

31 March 2020

1 reference

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

31 March 2020

1 reference

Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo

31 March 2020

1 reference

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

31 March 2020

1 reference

Immunologic correlates of the abscopal effect in a patient with melanoma

31 March 2020

1 reference

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

31 March 2020

1 reference

A new therapeutic strategy for malaria: targeting T cell exhaustion

31 March 2020

1 reference

Nivolumab in previously untreated melanoma without BRAF mutation

31 March 2020

1 reference

Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade.

31 March 2020

1 reference

PD-1 and its ligands in tolerance and immunity

31 March 2020

1 reference

Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective

31 March 2020

1 reference

5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity

31 March 2020

1 reference

Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model

31 March 2020

1 reference

Prerequisites for the antitumor vaccine-like effect of chemotherapy and radiotherapy

31 March 2020

1 reference

Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells

31 March 2020

1 reference

Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids

31 March 2020

1 reference

BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer

31 March 2020

1 reference

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

31 March 2020

1 reference

The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition

31 March 2020

1 reference

Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade

31 March 2020

1 reference

Hepatotoxicity with combination of vemurafenib and ipilimumab

31 March 2020

1 reference

History of myeloid-derived suppressor cells

31 March 2020

1 reference

MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy

31 March 2020

1 reference

Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling.

31 March 2020

1 reference

Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab

31 March 2020

1 reference

VEGF as a mediator of tumor-associated immunodeficiency

31 March 2020

1 reference

The role of neuropilins in cancer

31 March 2020

1 reference

Neuropilin 1: function and therapeutic potential in cancer

31 March 2020

1 reference

T cells: neuropilin 1 - distinguishing TReg cell subsets

31 March 2020

1 reference

Neuropilins: a new target for cancer therapy

31 March 2020

1 reference

A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors

31 March 2020

1 reference

A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors

31 March 2020

1 reference

Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis.

31 March 2020

1 reference

Historical review: Cytokines as therapeutics and targets of therapeutics

31 March 2020

1 reference

Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy

31 March 2020

1 reference

Immune responses in 4-1BB (CD137)-deficient mice

31 March 2020

1 reference

Targeting CD137 enhances the efficacy of cetuximab.

31 March 2020

1 reference

CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor.

31 March 2020

1 reference

OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy

31 March 2020

1 reference

PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer

31 March 2020

1 reference

Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer

31 March 2020

1 reference

Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation

31 March 2020

1 reference

Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin

31 March 2020

1 reference

Phase I/II clinical trial of anti-OX40, radiation and cyclophosphamide in patients with prostate cancer: immunological analysis

31 March 2020

1 reference

OX40 is a potent immune-stimulating target in late-stage cancer patients

31 March 2020

1 reference

Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation

31 March 2020

1 reference

Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs

31 March 2020

1 reference

CD70 as a therapeutic target in human malignancies

31 March 2020

1 reference

The death receptor 3/TL1A pathway is essential for efficient development of antiviral CD4⁺ and CD8⁺ T-cell immunity.

31 March 2020

1 reference

Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human

31 March 2020

1 reference

The TNF-family receptor DR3 is essential for diverse T cell-mediated inflammatory diseases

31 March 2020

1 reference

Triggering of TNFRSF25 promotes CD8⁺ T-cell responses and anti-tumor immunity

31 March 2020

1 reference

Immunobiology of TNFSF15 and TNFRSF25.

31 March 2020

1 reference

T cell costimulation by TNFR superfamily (TNFRSF)4 and TNFRSF25 in the context of vaccination

31 March 2020

1 reference

The molecular architecture of the TNF superfamily

31 March 2020

1 reference

Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment

31 March 2020

1 reference

Systemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver Damage

31 March 2020

1 reference

CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator

31 March 2020

1 reference

BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination

31 March 2020

1 reference

Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunity

31 March 2020

1 reference

BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1

31 March 2020

1 reference

Role of LAG-3 in regulatory T cells.

31 March 2020

1 reference

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape

31 March 2020

1 reference

Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer

31 March 2020

1 reference

A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma

31 March 2020

1 reference

First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity

31 March 2020

1 reference

A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma

31 March 2020

1 reference

Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family

31 March 2020

1 reference

TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity

31 March 2020

1 reference

Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection

31 March 2020

1 reference

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

31 March 2020

1 reference

The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity

31 March 2020

1 reference

CEACAM1 regulates TIM-3-mediated tolerance and exhaustion

31 March 2020

1 reference

T Cell/Transmembrane, Ig, and Mucin-3 Allelic Variants Differentially Recognize Phosphatidylserine and Mediate Phagocytosis of Apoptotic Cells

31 March 2020

1 reference

Emerging Tim-3 functions in antimicrobial and tumor immunity

31 March 2020

1 reference

Galectin-9 controls the therapeutic activity of 4-1BB-targeting antibodies

31 March 2020

1 reference

Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9

31 March 2020

1 reference

Siglecs and immune regulation

31 March 2020

1 reference

Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance

31 March 2020

1 reference

Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer

31 March 2020

1 reference

The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-β secretion from monocytes/macrophages through the DAP12-Syk pathway.

31 March 2020

1 reference

The blockade of immune checkpoints in cancer immunotherapy

31 March 2020

1 reference

Molecular mechanisms of T cell co-stimulation and co-inhibition

31 March 2020

1 reference

HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function

31 March 2020

1 reference

Mechanisms of costimulation

31 March 2020

1 reference

Targeting costimulatory molecules to improve antitumor immunity.

31 March 2020

1 reference

Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy

31 March 2020

1 reference

Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy

31 March 2020

1 reference

Functional clustering of immunoglobulin superfamily proteins with protein-protein interaction information calibrated hidden Markov model sequence profiles

31 March 2020

1 reference

VISTA Regulates the Development of Protective Antitumor Immunity

31 March 2020

1 reference

Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein

31 March 2020

1 reference

B7-H5 costimulates human T cells via CD28H

31 March 2020

1 reference

BTNL2, a butyrophilin-like molecule that functions to inhibit T cell activation

31 March 2020

1 reference

Sarcoidosis is associated with a truncating splice site mutation in BTNL2.

31 March 2020

1 reference

Immune modulation by butyrophilins

31 March 2020

1 reference

Germline missense variants in the BTNL2 gene are associated with prostate cancer susceptibility

31 March 2020

1 reference

Butyrophilins: an emerging family of immune regulators

31 March 2020

1 reference

Functional Classification of Immune Regulatory Proteins

31 March 2020

1 reference

DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins

31 March 2020

1 reference

Mechanisms of TIGIT-driven immune suppression in cancer

31 March 2020

1 reference

TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients

31 March 2020

1 reference

The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function

31 March 2020

1 reference

Immunosurveillance and therapy of multiple myeloma are CD226 dependent

31 March 2020

1 reference

Analysis of loss-of-function variants and 20 risk factor phenotypes in 8,554 individuals identifies loci influencing chronic disease

31 March 2020

1 reference

Correlation between NK function and response to trastuzumab in metastatic breast cancer patients

31 March 2020

1 reference

A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission

31 March 2020

1 reference

Roles of the NKG2D immunoreceptor and its ligands

31 March 2020

1 reference

Hematological malignancies escape from NK cell innate immune surveillance: mechanisms and therapeutic implications

31 March 2020

1 reference

Targeting MICA with therapeutic antibodies for the treatment of cancer

31 March 2020

1 reference

The inhibitory NK cell receptor CD94/NKG2A and the activating receptor CD94/NKG2C bind the top of HLA-E through mostly shared but partly distinct sets of HLA-E residues

31 March 2020

1 reference

Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity

31 March 2020

1 reference

HLA-G and immune evasion in cancer cells

31 March 2020

1 reference

Some basic aspects of HLA-G biology

31 March 2020

1 reference

The immunosuppressive molecule HLA-G and its clinical implications

31 March 2020

1 reference

2B4 (CD244), NTB-A and CRACC (CS1) stimulate cytotoxicity but no proliferation in human NK cells

31 March 2020

1 reference

Identification of a novel signal transduction surface molecule on human cytotoxic lymphocytes

31 March 2020

1 reference

Prospects for the use of NK cells in immunotherapy of human cancer.

31 March 2020

1 reference

A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors

31 March 2020

1 reference

Integrin-TGF-beta crosstalk in fibrosis, cancer and wound healing

31 March 2020

1 reference

Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model

31 March 2020

1 reference

TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer

31 March 2020

1 reference

Inhibition of TGF-β enhances the in vivo antitumor efficacy of EGF receptor-targeted therapy

31 March 2020

1 reference

Targeting hypoxia in cancer therapy

31 March 2020

1 reference

A2A adenosine receptor protects tumors from antitumor T cells.

31 March 2020

1 reference

Adenosine A2A receptors intrinsically regulate CD8+ T cells in the tumor microenvironment

31 March 2020

1 reference

Towards next generation adenosine A(2A) receptor antagonists

31 March 2020

1 reference

Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade

31 March 2020

1 reference

Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells

31 March 2020

1 reference

Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs

31 March 2020

1 reference

Immunological mechanisms of the antitumor effects of supplemental oxygenation

31 March 2020

1 reference

Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment

31 March 2020

1 reference

Targeting the adenosine A2b receptor in the tumor microenvironment overcomes local immunosuppression by myeloid-derived suppressor cells.

31 March 2020

1 reference

Myeloid suppressor cell depletion augments antitumor activity in lung cancer

31 March 2020

1 reference

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer

31 March 2020

1 reference

Plasma Protein β-2-Glycoprotein 1 Mediates Interaction between the Anti-tumor Monoclonal Antibody 3G4 and Anionic Phospholipids on Endothelial Cells

31 March 2020

1 reference

Antibody-mediated blockade of phosphatidylserine enhances the anti-tumor activity of targeted therapy and immune checkpoint inhibitors by affecting myeloid and lymphocyte populations in the tumor microenvironment

31 March 2020

1 reference

Antibody-mediated phosphatidylserine blockade significantly enhances the efficacy of downstream immune checkpoint inhibition in K1735 mouse melanoma

31 March 2020

1 reference

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

31 March 2020

1 reference

Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response

31 March 2020

1 reference

Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies

31 March 2020

1 reference

CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis

31 March 2020

1 reference

Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma

31 March 2020

1 reference

Therapeutic vaccines for cancer: an overview of clinical trials

31 March 2020

1 reference

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

31 March 2020

1 reference

Lymphocytic infiltration and survival in rectal cancer

31 March 2020

1 reference

Tumor immunosurveillance in human cancers

31 March 2020

1 reference

Cancer classification using the Immunoscore: a worldwide task force

31 March 2020

1 reference

From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer

31 March 2020

1 reference

12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy?

31 March 2020

1 reference

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

31 March 2020

1 reference

Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer

31 March 2020

1 reference

PD-1 blockade induces responses by inhibiting adaptive immune resistance

31 March 2020

1 reference

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

31 March 2020

1 reference

Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells

31 March 2020

1 reference

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

31 March 2020

1 reference

Vitiligo in patients with metastatic melanoma: a good prognostic sign

31 March 2020

1 reference

Prognostic significance of hypopigmentation in malignant melanoma

31 March 2020

1 reference

Primary hypothyroidism associated with interleukin-2 and interferon alpha-2 therapy of melanoma and renal carcinoma

31 March 2020

1 reference

Antiphospholipid syndrome associated with immunotherapy for patients with melanoma

31 March 2020

1 reference

Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells

31 March 2020

1 reference

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

31 March 2020

1 reference

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

31 March 2020

1 reference

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

31 March 2020

1 reference

Ipilimumab in patients with melanoma and autoimmune disease

31 March 2020

1 reference

Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial

31 March 2020

1 reference

MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF.

31 March 2020

1 reference

Phase 1 dose‐escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma

31 March 2020

1 reference

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

31 March 2020

1 reference

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

31 March 2020

1 reference

The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer

31 March 2020

1 reference

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

31 March 2020

1 reference

Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells

31 March 2020

1 reference

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

31 March 2020

1 reference

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

31 March 2020

1 reference

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

31 March 2020

1 reference

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

31 March 2020

1 reference

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--response

31 March 2020

1 reference

Programmed death-ligand 1 (PD-L1) expression in various tumor types

31 March 2020

1 reference

Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production

31 March 2020

1 reference

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

31 March 2020

1 reference

Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer

31 March 2020

1 reference

Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer.

31 March 2020

1 reference

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

31 March 2020

1 reference

Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma

31 March 2020

1 reference

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

31 March 2020

1 reference

Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain

31 March 2020

1 reference

B7-H3 and B7-H4 expression in non-small-cell lung cancer

31 March 2020

1 reference

Relationship between co-stimulatory molecule B7-H3 expression and gastric carcinoma histology and prognosis

31 March 2020

1 reference

Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma

31 March 2020

1 reference

Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer

31 March 2020

1 reference

Clinical significance and regulation of the costimulatory molecule B7-H3 in human colorectal carcinoma

31 March 2020

1 reference

Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas

31 March 2020

1 reference

B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy

31 March 2020

1 reference

T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival

31 March 2020

1 reference

B7-h4 is highly expressed in ductal and lobular breast cancer

31 March 2020

1 reference

B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival

31 March 2020

1 reference

B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma

31 March 2020

1 reference

B7-H4 Is a Novel Membrane-Bound Protein and a Candidate Serum and Tissue Biomarker for Ovarian Cancer

31 March 2020

1 reference

B7-H4 overexpression in ovarian tumors

31 March 2020

1 reference

B7-H4 expression associates with cancer progression and predicts patient's survival in human esophageal squamous cell carcinoma.

31 March 2020

1 reference

Clinical significance of the B7-H4 coregulatory molecule as a novel prognostic marker in gastric cancer

31 March 2020

1 reference

Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer

31 March 2020

1 reference

Alpha 1 antichymotrypsin is aberrantly expressed during melanoma progression and predicts poor survival for patients with metastatic melanoma

31 March 2020

1 reference

Detection of B7-H4 and p53 in pancreatic cancer: potential role as a cytological diagnostic adjunct.

31 March 2020

1 reference

B7-h4 expression in human melanoma: its association with patients' survival and antitumor immune response

31 March 2020

1 reference

Galectin expression profiling identifies galectin-1 and Galectin-9Δ5 as prognostic factors in stage I/II non-small cell lung cancer

31 March 2020

1 reference

Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures

31 March 2020

1 reference

Lactose-binding lectin expression in human colorectal carcinomas. Relation to tumor progression

31 March 2020

1 reference

CD70 expression patterns in renal cell carcinoma

31 March 2020

1 reference

CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells

31 March 2020

1 reference

Expression of the B7-related molecule ICOSL by human glioma cells in vitro and in vivo

31 March 2020

1 reference

Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells

31 March 2020

1 reference

CD155/PVR plays a key role in cell motility during tumor cell invasion and migration

31 March 2020

1 reference

Prognostic and predictive markers for the new immunotherapies.

31 March 2020

1 reference

12 December 2020

Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin 2 in mice

1 reference

12 December 2020

Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function

1 reference

12 December 2020

Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy

1 reference

12 December 2020

Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review).

1 reference

12 December 2020

Blocking IDO activity to enhance anti-tumor immunity.

1 reference

12 December 2020

Ki-1 (CD30) antigen is regularly expressed by tumor cells of embryonal carcinoma

1 reference

12 December 2020

Increased expression of galectin-3 in primary gastric cancer and the metastatic lymph nodes

1 reference

12 December 2020

Serum VEGF level is associated with the outcome of patients with hepatocellular carcinoma: a meta-analysis

1 reference

12 December 2020

NKG2D ligands as therapeutic targets

1 reference

12 December 2020

Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients.

1 reference

12 December 2020

Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade.

1 reference

12 December 2020

Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects.

1 reference

12 December 2020

Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD4591

1 reference

Dimensions Publication ID

2 August 2017

1016866071

0 references

1 reference